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Chordomas are malignant tumors that originate in embryonic notochordal remnants. The sacrum and
skull are the most common sites; the mobile spine and other bones are extremely rare sites. We describe
a 45-year-old man who presented with a lytic lesion in his left ilium. Imaging and pathology of a biopsy
specimen suggested a malignant bone tumor; wide resection was accordingly performed. The mor-
phology and immunohistochemistry of the operative specimen showed obvious characteristics of classic
chordoma. To our knowledge, this is the ﬁrst reported case of a chordoma originating in the ilium.
Chordoma should therefore be considered in the differential diagnosis of lytic lesions in the ilium.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Chordomas, rare malignant tumors that originate in embryonic
notochordal remnants, account for 1–4% of primary malignant
bone tumors [1]. Their origin from notochordal cells was ﬁrst re-
ported by Muller in 1858; the tumors were named by Ribbert in
1894. Their incidence is only 0.5–0.8/million and they account for
17.5% of primary malignant bone tumors in axial bones [1,2]. Most
chordomas occur in the sacrococcygeal region. About 50–60%
originate in the sacrum, and 15% in the skull and mobile spine
[3,4]. Chordomas in other sites are extremely rare.
We here present the clinical, radiographic, and histologic
ﬁndings as well as treatment and outcome in a patient with an
iliac chordoma. To the best of our knowledge, a chordoma located
in the ilium has never been reported.2. Case report
A 45-year-old man presented to our institution with left low
back pain with no obvious cause for two months. The pain oc-
curred when climbing stairs or bending over, not at rest or during
the night. Concurrent with its worsening, he had noticed an en-
larging mass on his lower back.
On physical examination the patient appeared healthy, but in mildGmbH. This is an open access art
niuxiaohui@263.net (X. Niu),
).discomfort. No erythema, varicose or ruptured veins were found. The
skin temperature over the lesionwas normal. There was a tender, non-
compressible, diffuse swelling over the posterior aspect of the left
ilium that did not change with bending down, although this did in-
crease his pain. His gait and range of hip joint motion appeared nor-
mal, as did muscle strength and sensation in his lower limbs.
Radiographs showed a lytic lesion in the left ilium adjacent to
the sacroiliac joint (Fig. 1). Computed tomography (CT) (Fig. 2)
showed a 5.55.03.4 cm3 lytic lesion in the left ilium; the sa-
crum was not involved. The lesion was of uniform density with no
bone or cartilage matrix formation. The cortex was discontinuous
and the boundary well-deﬁned. CT values were 39 HU before en-
hancement and 57 HU after enhancement. A chest CT revealed no
lung lesions. Magnetic resonance imaging showed medium and
high signals in T1- and T2-weighted images, respectively, with
uneven enhancement. The maximum standardized uptake value
on positron emission tomography was 2.9 and no other lesions
were detected. Serum alkaline phosphatase, calcium and phos-
phate concentrations were normal.
A core needle biopsy showed a funicular, or cluster, structure of
vacuolated tumor cells in a background of mucus. The cells re-
sembled chordoma cells and appeared mildly atypical. No clearly
differentiated cartilage or bone was found.
We made a diagnosis of malignant bone tumor based on the
imaging and pathology ﬁndings, and made the decision to perform
computer navigation-aided wide resection. We chose an iliac groin
approach extending to the posterior inferior iliac spine. We pro-
tected the femoral nerve and lateral cutaneous nerve while ex-
posing the sacrum and ilium. We cut the bone in accordance with
the pre-operative plan and completely excised the tumor, leavingicle under the CC BY-NC-ND license
Fig.1. Preoperative X ray and CT showed osteolytic destruction of the left iliac wing. The density was uniform and the cortical bone was not continuous. The sacrumwas not
involved.
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ilium to ﬁll the defect.
Pathological examination of the operative specimen showed that
a wide resection margin had been achieved (Fig. 3). We again ob-
served a funicular structure of vacuolated tumor cells in a back-
ground of mucus. The cells had a mildly atypical appearance. Im-
munohistochemical staining showed the following: cytokeratin (CK)
(þþþ), CK7 (focal þ), CK8 (þþþ), CK18 (focal þ), CK19 (þþþ),
epithelial membrane antigen (focal weak þ), S-100 (scattered cells
þ), D2-40 (), brachyury (þ), and vimentin (þ). Therefore, the
microstructure, morphology and immunohistochemistry results
were consistent with a classical chordoma diagnosis (Fig. 4).
No tumor recurrence was detected during 9 months of follow-
up, during which time the patient resumed normal daily life ac-
tivities and achieved a 90% Musculoskeletal Tumor Society score.3. Discussion
The most common site of chordomas is the sacrum, but theyFig.2. Preoperative MRI showed moderate signal on T1 andcan also occur in the base of the cranium and the mobile spine
[5,6]. Most patients with chordomas are in their ﬁfth to seventh
decades. The ratio of male to female patients is about 2–3:1. Be-
cause affected patients often present with a long history of sacral
or ﬂank pain, diagnosis and treatment are often delayed. When
these tumors enlarge, they can invade pelvic organs or nerve roots,
causing organ and lower limb dysfunction.
Radiographs usually show cystic and expansible osteolytic le-
sions with bone shell discontinuity. CT scans can clearly show the
extent of the soft tissue mass and associated destruction. These
tumors often show low to moderate signals and high signals in
MRI T1- and T2-weighted imaging, respectively, and can appear
lobulated. Pathological examination characteristically shows a
gray-brown or white, translucent, jelly-like lesion with uneven
texture and a pseudo capsule. The tumor cells usually form masses
or cords. Chordomas are classiﬁed into three types according to
cell morphology: common, chondroid, and poorly differentiated.
The common type is low grade with droplet-like vacuoles in the
tumor cells.
It is extremely rare for chordomas to occur in sites other thanhigh signal on T2 with inhomogeneous enhancement.
Fig.3. Assessment of postperative specimen showed tumor located in ilium without involvement of the sacrum.
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found any previous reports of iliac chordomas. In theory, chordo-
mas can only occur in sites that were occupied by the embryonic
notochord. These sites include the whole length of the spine from
the skull base to the sacrum, most commonly at one end or the
other. Imaging studies of this rare tumor showed the iliac lesion
was adjacent to the sacrum; however, it appeared to have origi-
nated from the ilium without any involvement of the sacrum. An
biopsy revealed chordoma, which was completely unexpected. The
pathologists therefore carefully reviewed the pathology of the
operative specimen and again concluded the diagnosis was chor-
doma. This rare case changed our understanding of both chordo-
mas and primary iliac tumors. We could ﬁnd only case reports of aFig.4. The postoperative pathology showed funicular or cluster structure atypia vacuol
nuclei and mild atypia. Multiple vacuoles were showed in cytoplasm (b) (HE staining Xchordoma occurring in non-axial bone [3].
The most common primary malignant tumor of the ilium is
chondrosarcoma; osteosarcoma, Ewing sarcoma, and malignant
ﬁbrous histiocytoma are also common, whereas other primary
malignant bone tumors are rare [4]. Common benign tumors of
the ilium include giant cell tumors, osteochondromas, simple bone
cysts, and ﬁbrous dysplasia; chondroblastomas, Langerhans cell
disorders, and bone hemangiomas can also occur [4].
Our patient was a 45-year-old man, which is consistent with
the reported age range and sex for subjects with chordomas. These
lesions should be differentiated from other benign and malignant
tumors. Chondrosarcomas are the most frequent primary malig-
nant bone tumor of the ilium, usually occurring in persons agedated tumor cells in background of mucus (a). Droplet like tumor cells with round
200). The tumor cells were positive for Brachyury (c) and CK8 (d) (EnVision X 200).
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struction with well-demarcated boundaries, as was true in our
case. However, a calciﬁed matrix and obvious soft tissue mass are
characteristically found in subjects with chondrosarcomas. Os-
teosarcomas occur mainly in adolescents, but have been reported
in older patients with pelvic lesions [4]. These high grade tumors
usually cause severe local symptoms and have aggressive char-
acteristics. About 5% of giant cell tumors occur in the pelvis [8],
and affected patients are characteristically younger than our case.
Imaging shows osteolytic destruction with no bone or cartilage
matrix formation. These lesions usually have obvious cortical ex-
pansive growth with soap bubble-like changes. A liquid plane can
be found on MRI examination. Thus, the ﬁndings in our case are
inconsistent with any other common malignant tumor.
In our case, radiographs showed osteolytic destruction of uni-
form density. No bone or cartilage matrix formation was evident,
these ﬁndings being similar to the classic manifestations of chor-
doma; however, there were some differences. The MRI signals
were fairly uniform and there was no obvious soft tissue mass,
whereas sacral chordoma often appear as large, lobulated, het-
erogeneous, soft tissue masses; possibly because sacral chordomas
tend to have occult symptoms and diagnosis is usually delayed.
However, our case was diagnosed only two month after onset of
symptoms.
The standard therapy for chordoma is excision. Local recur-
rence, but not metastasis, is a major determinant of prognosis.
Because local recurrence is related to initial surgical margin and
intra-operative tumor cell contamination, achieving a safe margin
is very important. Boriani [6] reported 153 cases of chordoma
patients who underwent surgery. The recurrence and survival
rates were 26.2% and 86.2%, respectively, for patients with safe
margins; they were 78.4% and 58%, respectively, for those receiv-
ing intralesional resection. Others have reported recurrence rates
of 43–85% [9–12]. Wide resection can signiﬁcantly reduce the re-
currence rate; however, it is often very difﬁcult to achieve. Fuchs
[13] reported 31 cases with wide resection, only one of whom
relapsed. However, 22 of 31 patients in whom wide margins were
not achieved relapsed. Yonemoto [14] reported a recurrence rate
after intracapsular resection of 60%; no patients in whom wide
resection was achieved relapsed. In our patient, wide excision of
the iliac lesion was achieved and the patient made a good func-
tional recovery and has had no recurrence.
Boriani [6] reported that patients who have undergone in-
tralesional resection and have residual tumors can beneﬁt from
postoperative radiotherapy. Many recent studies [12,15,16] have
reported that postoperative radiotherapy can relieve pain and
prolong disease-free survival. Reported 5-year and 10-year survi-
val rates are 45–87% and 28–71%, respectively. Some factors such
as being male, younger age, smaller tumor, and early treatment
may be associated with a good prognosis [1,6,9–14,17,18].
A possible explanation for the occurrence of our patient's
chordoma in the ilium near the sacrum is ectopic growth of no-
tochord tissue. Our patient was fortunate to receive an early, ac-
curate diagnosis and effective treatment.Conﬂict of interest statement
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